Event-free survival of younger patients (18-60 years, LDH ≤ UNV). Panel A refers to patients treated on the NHL-B1 trial. Panel B refer to patients treated on the NHL-B1 or Hi-CHOEP phase II/III trials. Patients who did or did not receive etoposide plus CHOP (CHOEP) are compared. Panels C and D show the EFS for patients with ALCL, ALK-positive (C), and with other major subtypes (D).